Search research articles
Contact Us
Filters
Showing results (71-80 of 132) with videos related to
Page
of 14
Sort By:
Therapeutic Drug Monitoring
|
April 22, 2006
Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities
Cédric Mercier, Joseph Ciccolini, Bertrand Pourroy, et al.
Journal of Geriatric Oncology
|
July 31, 2021
Functional status in older patients with cancer
Anne-Laure Couderc, Pierre Suchon, Bérengère Saliba-Serre, et al.
Annals of Surgical Oncology
|
September 30, 2023
Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial
Sylvie Bonvalot, Nathalie Cozic, Axel Le Cesne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2019
Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Maud Toulmonde, Jean-Yves Blay, Olivier Bouche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2019
Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Maud Toulmonde, Jean-Yves Blay, Olivier Bouche, et al.
British Journal of Clinical Pharmacology
|
November 6, 2018
Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort
Florence Daviet, Franck Rouby, Pascale Poullin, et al.
BMC Cancer
|
March 7, 2014
Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group
Thanh-Khoa Huynh, Pierre Meeus, Philippe Cassier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2007
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group
Jean-Yves Blay, Axel Le Cesne, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2015
Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group
Anna Patrikidou, Julien Domont, Sylvie Chabaud, et al.
Cancer Chemotherapy and Pharmacology
|
March 6, 2010
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity
Chen Guang Yang, Joseph Ciccolini, Aurore Blesius, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 132) with videos related to
Sort By:
Page
of 14
Therapeutic Drug Monitoring
|
April 22, 2006
Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities
Cédric Mercier, Joseph Ciccolini, Bertrand Pourroy, et al.
Journal of Geriatric Oncology
|
July 31, 2021
Functional status in older patients with cancer
Anne-Laure Couderc, Pierre Suchon, Bérengère Saliba-Serre, et al.
Annals of Surgical Oncology
|
September 30, 2023
Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial
Sylvie Bonvalot, Nathalie Cozic, Axel Le Cesne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2019
Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Maud Toulmonde, Jean-Yves Blay, Olivier Bouche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2019
Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Maud Toulmonde, Jean-Yves Blay, Olivier Bouche, et al.
British Journal of Clinical Pharmacology
|
November 6, 2018
Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort
Florence Daviet, Franck Rouby, Pascale Poullin, et al.
BMC Cancer
|
March 7, 2014
Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group
Thanh-Khoa Huynh, Pierre Meeus, Philippe Cassier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2007
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group
Jean-Yves Blay, Axel Le Cesne, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2015
Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group
Anna Patrikidou, Julien Domont, Sylvie Chabaud, et al.
Cancer Chemotherapy and Pharmacology
|
March 6, 2010
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity
Chen Guang Yang, Joseph Ciccolini, Aurore Blesius, et al.
Page
of 14